Drugs / TROMETHAMINE
last change Jul 2026 re-read 2 minutes ago

TROMETHAMINE

Small molecule

Developed for
metabolic acidosis
Investigated by
Lakshmi Durairaj · Mayo Clinic

Trials 2 · a red edge is where a trial was stopped

2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03078088 Jun 2017 → Feb 2019 cystic fibrosis Lakshmi Durairaj Completed No outcome recorded
Phase 41 trial
Phase 4 NCT07424625 Jul 2026 → Feb 2027 expected metabolic acidosis Mayo Clinic Not yet recruiting No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as TROMETHAMINE ChEMBL registry synonym — accepted as the source's own label CHEMBL1200391
Known as NSC-6365 ChEMBL registry synonym — accepted as the source's own label CHEMBL1200391
Known as Tham ClinicalTrials.gov intervention name — accepted as the source's own label NCT03078088
Known as Tris-base ChEMBL registry synonym — accepted as the source's own label CHEMBL1200391
Known as Tris-hydroxymethyl Aminomethane ClinicalTrials.gov intervention name — accepted as the source's own label NCT07424625
Known as Trizma ChEMBL registry synonym — accepted as the source's own label CHEMBL1200391
Known as Tromethamine component of tham-e ChEMBL registry synonym — accepted as the source's own label CHEMBL1200391
Modality Small molecule CHEMBL1200391